obesity

News

Veru shares plunge despite positive data in obesity trial

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.

Patients

social media illustration overlay on smart phone use

Social media advocacy: Healthcare professionals and the Trea...

Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum.

News

Novo Nordisk leaps on new obesity drug data

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

News

Large study points to benefits - and risks - of GLP-1 drugs

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

Veru shares plunge despite positive data in obesity trial

Social media advocacy: Healthcare professionals and the Trea...

Novo Nordisk leaps on new obesity drug data

Large study points to benefits - and risks - of GLP-1 drugs

High-dose semaglutide ramps up weight loss, says Novo

Lilly trims sales forecast on weaker obesity/diabetes growth

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks